Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Atypical CML Distinct From Related Myelodysplastic/Myeloproliferative Disorders

May 7, 2014
By Dave Levitan
News
Article

A rare subtype of disease known as atypical chronic myeloid leukemia (aCML) has been shown to be clinically distinct from a related condition known as unclassifiable myelodysplastic/myeloproliferative neoplasm.

A rare subtype of disease known as atypical chronic myeloid leukemia (aCML) has been shown to be clinically distinct from a related condition known as unclassifiable myelodysplastic/myeloproliferative neoplasm (MDS/MPN-U). Several clinical and genetic factors seem to differentiate these diseases.

In a 2008 World Health Organization attempt at classifying diseases falling under the MDS/MPN umbrella, aCML was defined by persistent leukocytosis, marked dysgranulopoiesis, and minimal or no monocytosis or basophilia. The presence of BCR-ABL1 or several other genetic rearrangements precludes an aCML diagnosis. For this study, led by Sa A. Wang, MD, of MD Anderson Cancer Center in Houston, researchers analyzed patient archives for 134 patients at 7 large medical centers; results were published in the April 24 issue of Blood.

All patients were confirmed to lack BCR-ABL1. Of the full cohort, 65 cases (49%) fulfilled the three main aCML criteria of persistent leukocytosis, “marked” dysgranulopoiesis (the authors used a ≥ 10% granulocytes cutoff, lacking a specific measure in the WHO guidelines), and greater than 10% myeloid precursors. Those cases were assigned a diagnosis of aCML, while the remaining 69 were diagnosed as MDS/MPN-U.

“Notably, substantial overlapping features between MDS/MPN-U and aCML were observed,” the authors wrote. About 31% of the cohort fulfilled two of the three of those main criteria. Also, though the other WHO criterion of “no basophilia (often ≤ 2% basophils)” was not used for exclusion, the cases that were defined as aCML had a median basophil percentage of 0% and only two patients had greater than 2% basophils.

The researchers found a number of clinical and histological differences between the two groups of patients. Compared with MDS/MPN-U patients, aCML patients had “more frequently increased LDH, organomegaly, worse anemia, thrombocytopenia, higher circulating blasts, and a lower basophil percentage.” The median white blood cell count was significantly higher for aCML patients, at 40.8 × 109 vs 19.4 × 109 (P < .0001).

Treatments given to the two groups were similar. Those with aCML had a median overall survival of 12.4 months and an acute myeloid leukemia (AML)-free survival of 11.2 months; both were significantly worse than with the MDS/MPN-U patients, who had an overall survival of 21.8 months and an AML-free survival of 18.9 months (P = .004 and .003, respectively).

Genotyping showed some differences that did not reach significance, including slightly more mutated RAS with aCML (35% vs 14%), and less JAK2p.V617F (7% vs 19%).

“In summary, we showed that the WHO definition for aCML identifies within the MDS/MPN category a distinct subgroup of patients with a number of adverse clinical features as well as inferior outcomes,” the authors concluded.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content
Advertisement

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

Russ Conroy
July 24th 2025
Article

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
July 23rd 2025
Article

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.

Cyclophosphamide-Based GVHD Prophylaxis May Improve Survival in HSCT

Roman Fabbricatore
July 21st 2025
Article

Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.


The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial

Tim Cortese
July 16th 2025
Article

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

Related Content
Advertisement

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

Russ Conroy
July 24th 2025
Article

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
July 23rd 2025
Article

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.

Cyclophosphamide-Based GVHD Prophylaxis May Improve Survival in HSCT

Roman Fabbricatore
July 21st 2025
Article

Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.


The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial

Tim Cortese
July 16th 2025
Article

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.